BIOVIE INC. (BIVI) Stock Profile — Insider Trades & Financials

Net Income-$6.1M

EPS$-1.70

Market Cap$11.2M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Cuong Viet Do

CEO & Executive Director

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimerâs disease; and in Phase 2 clinical trial to treat Parkinsonâs disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Founded: 2013
Employees: 13
Headquarters: Carson City, Nevada, United States

⚡

Core Efficiency

ROE?

-31.51%

ROA?

-26.97%

D/E Ratio?

0.17

📊

Profitability Ratios

Current Ratio?

7.25

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

May 9, 2026 (in 30 days)

Quarterly Report (10-Q) — Based on filing pattern

May 9, 2026

Predicted10-Q

Feb 6, 2026

10-QQ2 20261d after period end

Nov 10, 2025

10-QQ1 20263d after period end

Aug 15, 2025

10-KQ4 20250d after period end

May 12, 2025

10-QQ3 20257d after period end

Feb 11, 2025

10-QQ2 20254d after period end

Nov 13, 2024

10-QQ1 20246d after period end

Sep 30, 2024

10-KQ4 20245d after period end

May 14, 2024

10-QQ3 20234d after period end

Loading company sections...

BIOVIE INC.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness